The tweet was deleted by the author.
But we saved everything 🙂.
Insmed said U.S. regulators have granted Priority Review to its supplemental New Drug Application for a lung disease therapy. The stock is down 3% on the day at $120.
The company said the FDA has granted Priority Review to its supplemental New Drug Application for its Mycobacterium avium complex lung disease therapy. The review carries a target action date of January 28, 2027. All 91 analysts who cover the stock currently rate it a buy.
View post on X Loading...
The latest session saw an intraday range expand well beyond the weekly average, with prices moving between $119.62 and $124.1. Shares of Insmed are trading below the MA-20 and MA-200 but remain above the MA-50, reflecting a split daily structure. The overall move fits within a bearish chart setup. Stoch RSI is in oversold territory, indicating that downside risk is becoming stretched and may limit further declines.
Traders should watch whether Insmed stock closes above $124.14 or drops below $118.49 to gauge market acceptance of the recent move. The wide spread between $119.62 and $124.1 during the latest session underscores ongoing volatility. Over the next five trading days, the probability of further downside stands at 67%, while the chance of upside is 33%, with price action expected within a $114.41 to $125.58 range. Even so, the past week has brought a sharp move lower without a sustained trend. A close above $124.14 would indicate buyers are gaining traction, while a drop below $118.49 would suggest the move is being rejected. On the weekly chart, the longer-term picture stays negative.
Earlier, analysts noted that Insmed’s bullish momentum was supported by rising commercial prospects and strong institutional interest. The Priority Review announcement introduces a regulatory catalyst to the story, but with the stock now reflecting a bearish daily structure and heightened volatility, traders should monitor $124.14 and $118.49 as the key levels likely to determine short-term direction.